Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay

PURPOSE: Previous studies have shown EndoPredict (EPclin), a test that integrates 12-gene expression data with nodal status and tumor size, to be predictive for risk of distant recurrence in women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Soliman, Hatem, Flake, Darl D., Magliocco, Anthony, Robson, Mark, Schwartzberg, Lee, Sharma, Priyanka, Brown, Krystal, Wehnelt, Saskia, Kronenwett, Ralf, Gutin, Alexander, Lancaster, Johnathan, Cuzick, Jack, Gradishar, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446472/
https://www.ncbi.nlm.nih.gov/pubmed/32914026
http://dx.doi.org/10.1200/PO.18.00361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446472/
https://www.ncbi.nlm.nih.gov/pubmed/32914026
http://dx.doi.org/10.1200/PO.18.00361

Ejemplares similares